News and blogs
162 results found.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
What we can achieve with £1 million
We're proud to announce We’ve invested over £1 million funding five research projects, across five different blood cancers
The story of Dr Jane C Wright, pioneer of blood cancer research
To mark the start of Black History Month, we share the story of Dr Jane C Wright, a true pioneer in the field of blood cancer research
The father of the blood bank - Charles R. Drew
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Myeloma drug approved for use
A new treatment for those with the blood cancer myeloma has been approved for use by NICE. It could benefit thousands.
Ruxolitinib approved for treatment of polycythaemia vera in England and Wales
The drug, ruxolitinib, has been recommended for use by NICE to treat the blood cancer polycythaemia vera in those whose disease is resistant or intolerant to the treatments hydroxycarbamide/hydroxyurea.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
National Cancer Research Institute to close.
Blood Cancer UK's Sarah McDonald said it's sad that this long-standing, multi-partner collaboration is winding down.
Blood Cancer UK have renewed their partnership with RareCan
Blood Cancer UK have renewed their partnership with RareCan, a digital health company. This could give people an opportunity to help researchers.
A new dawn for clinical trials
A new dawn for clinical trials to get us to a place where no lives are lost to blood cancer
Targeting tumor stroma could improve immunotherapy response in lymphoma
Blood Cancer UK researchers at King's College London have shown how specific cells known as ‘fibroblast cells’ in lymphoma tumours suppress the body’s immune cells and immunotherapy treatment.
Blood cancer drug ruxolitinib gives better outcomes than those on best-available existing medication
The drug, ruxolitinib, has been found to be better at treating the blood cancer - polycythaemia vera (PV) than the best currently available treatment.
Using motixafortide to treat multiple myeloma
New research suggests that motixafortide improves stem cell transplants for those with multiple myeloma.
How research could put an end to the fear of cancer returning
How research could put an end to the fear of cancer returning
Blood Cancer UK fund new research
Blood Cancer UK are funding 16 new research projects worth £14 million
CAR-T cell therapy made available on NHS
Yescarta has now been made available for people with certain types of lymphoma on the NHS in England
The origins of childhood leukaemia in twins
Blood Cancer UK's research funding has led to an understanding of the origins of childhood leukaemia in twins.
New ‘universal approach’ therapy for leukaemia shows promise during world-first trial
Blood Cancer UK was proud to fund the lab studies that directly led to this life-changing trial which could broaden the number of people who benefit from this type of therapy in future.
Paxlovid rebound - what we know
Paxlovid rebound is when people recover from covid-19 after taking a course of Paxlovid tablets, but then the infection seems to come back. Find out what this means for people offered treatment with Paxlovid.
Evusheld available in the UK to buy privately
Evusheld is available privately in the UK. Here’s what we know about how to access it.
